HK1255209A1 - 用於採用聚合物囊泡遞送基因編輯工具的組合物和方法 - Google Patents

用於採用聚合物囊泡遞送基因編輯工具的組合物和方法

Info

Publication number
HK1255209A1
HK1255209A1 HK18114337.3A HK18114337A HK1255209A1 HK 1255209 A1 HK1255209 A1 HK 1255209A1 HK 18114337 A HK18114337 A HK 18114337A HK 1255209 A1 HK1255209 A1 HK 1255209A1
Authority
HK
Hong Kong
Prior art keywords
delivery
compositions
methods
gene editing
editing tools
Prior art date
Application number
HK18114337.3A
Other languages
English (en)
Inventor
P Peter Ghoroghchian
Jivan Namdeo Yewle
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of HK1255209A1 publication Critical patent/HK1255209A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
HK18114337.3A 2015-07-02 2018-11-09 用於採用聚合物囊泡遞送基因編輯工具的組合物和方法 HK1255209A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187942P 2015-07-02 2015-07-02
US201662322346P 2016-04-14 2016-04-14
US15/199,021 US20170000743A1 (en) 2015-07-02 2016-06-30 Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
PCT/US2016/040673 WO2017004509A1 (en) 2015-07-02 2016-07-01 Compositions and methods for delivery of gene editing tools using polymeric vesicles

Publications (1)

Publication Number Publication Date
HK1255209A1 true HK1255209A1 (zh) 2019-08-09

Family

ID=57609243

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114337.3A HK1255209A1 (zh) 2015-07-02 2018-11-09 用於採用聚合物囊泡遞送基因編輯工具的組合物和方法

Country Status (8)

Country Link
US (1) US20170000743A1 (zh)
EP (1) EP3317414A4 (zh)
JP (2) JP6993966B2 (zh)
CN (1) CN108699563A (zh)
AU (1) AU2016288237B2 (zh)
CA (1) CA2991109A1 (zh)
HK (1) HK1255209A1 (zh)
WO (1) WO2017004509A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3105873A1 (en) 2016-09-30 2018-04-05 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102447083B1 (ko) 2016-10-06 2022-09-26 포세이다 테라퓨틱스, 인크. 유도성 카스파제 및 사용 방법
JP2020523383A (ja) 2017-06-14 2020-08-06 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
AU2018283405A1 (en) 2017-06-15 2020-01-16 The Regents Of The University Of California Targeted non-viral DNA insertions
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
CA3149892A1 (en) 2019-09-05 2021-03-11 Eric M. Ostertag Allogeneic cell compositions and methods of use
US20230079955A1 (en) 2019-12-20 2023-03-16 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
EP4118107A1 (en) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
BR112023021283A2 (pt) * 2021-04-13 2023-12-19 Arsenal Biosciences Inc Junção de extremidade mediada por homologia não viral
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023193665A1 (zh) * 2022-04-07 2023-10-12 威海纽兰生物科技有限公司 基于细胞外囊泡酯酶响应药物递送载体及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1286699A2 (en) 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
US20040265835A1 (en) * 2003-06-30 2004-12-30 Lemaster David M. Method of sorting vesicle-entrapped, coupled nucleic acid-protein displays
AU2010229872A1 (en) * 2009-03-26 2011-11-03 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory RNA for disease modification
EP2417262B1 (en) * 2009-04-07 2015-05-20 Dow AgroSciences LLC Nanoparticle mediated delivery of sequence specific nucleases
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
US20130202712A1 (en) * 2010-03-02 2013-08-08 Vindico Nanobio Technology, Inc. Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
US20140363496A1 (en) * 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
BR112013025567B1 (pt) * 2011-04-27 2021-09-21 Amyris, Inc Métodos para modificação genômica
PT2898075E (pt) * 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
MX2015007550A (es) * 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
EP2971167B1 (en) * 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20150067922A1 (en) * 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing

Also Published As

Publication number Publication date
JP2018532408A (ja) 2018-11-08
JP2019165745A (ja) 2019-10-03
EP3317414A1 (en) 2018-05-09
CN108699563A (zh) 2018-10-23
US20170000743A1 (en) 2017-01-05
JP6993966B2 (ja) 2022-02-04
WO2017004509A1 (en) 2017-01-05
EP3317414A4 (en) 2019-03-13
AU2016288237A1 (en) 2018-01-25
CA2991109A1 (en) 2017-01-05
AU2016288237B2 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
HK1255209A1 (zh) 用於採用聚合物囊泡遞送基因編輯工具的組合物和方法
HK1256817A1 (zh) 用於基因組編輯的組合物和方法
IL273817A (en) Preparations and methods for editing rna
HK1258900A1 (zh) 遞送方法和組合物
EP3362104A4 (en) METHODS AND COMPOSITIONS USING CPF1 FOR RNA-GUIDED GENETIC EDITION
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
HK1253674A1 (zh) 用於具有增强的穩定性的瞬時基因療法的組合物和方法
EP3322297A4 (en) RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING
EP3386484A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING THERAPEUTIC AGENTS
EP3350315A4 (en) METHODS FOR GENOME AUTOCATALYTIC EDITING AND NEUTRALIZATION OF GENOME AUTOCATALYTIC EDITION AND COMPOSITIONS THEREOF
EP3300507A4 (en) GENERIC ADMINISTRATION AND COMPOSITIONS
IL271232A (en) Compounds and methods for editing the genome
AP2016009588A0 (en) Multiplex gene editing in swine
EP3256170A4 (en) Compositions and methods for transient delivery of nucleases
EP3097212A4 (en) Methods and compositions for sequences guiding cas9 targeting
WO2017107898A9 (en) Compositions and methods for gene editing
EP3233192A4 (en) Compositions and methods for targeted cytokine delivery
IL258292A (en) Methods and compositions for reducing metastases
IL246879A0 (en) Preparations of Epilimod and methods of using them
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
EP3129753A4 (en) Compositions and methods for delivery of carbon dioxide
EP3294662A4 (en) MIXING DEVICE AND METHOD
EP3116489A4 (en) Methods and compositions for transdermal delivery
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
EP3389673A4 (en) METHODS AND COMPOSITIONS FOR ADMINISTRATION OF POLYNUCLEOTIDES